Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-27

@theoc
The vibe I picked up after the Azer-cel acquisition is that the quickest path to FDA registration is to target 2nd/3rd line treatment after patients have failed off the major existing drugs (SOC). That’s a setting where there are no standard treatment options so, there would be no need for expensive long running Ph3 head to head trials as Vaxinia could initially slot in as 2nd/3rd line SOC, possibly with accelerated approval. That would pave the quickest path to revenue which will bring about much better terms for a licensing agreement or acquisition.